Individualizing gMG Treatment: Defining Success With Each Patient

Announcer:
You’re listening to Neurofrontiers on ReachMD. Today, we’ll hear from Dr. Omar Sinno, who’s the US Medical Strategy Lead of Rare Disease at UCB in Atlanta. He shared recommendations for tailoring generalized myasthenia gravis, or gMG, management to fit patient needs and preferences at the AANEM 2025 Annual Meeting in San Francisco.

Here’s Dr. Sinno now.

Dr. Sinno: 
Success involves a lot of different things. Symptom control is one of them. I think success involves making sure that we understand patients more as newer treatments come out. As we know, gMG is a very individualized disease, so understanding more about our patients will allow for better care. And with respect to moving past symptom control, absolutely. I think there's a little bit more focus nowadays on understanding what the patients want besides just getting better. What are their goals? What are the things that they want to do that they couldn't have done in the past? And how, together, can we help them get there?

And I think with more and more therapies coming out, it's a very good opportunity for physicians to make sure that, of course, the physical component of the condition, or how the patient is doing, is taken care of, but also making sure that we know there are secondary components to that, for example. What is important to the patient with respect to the frequency of dosing. Is a daily dose okay? Do they want to go into the clinic every week? So making sure that a treatment works for them clinically but also works for them in their day-to-day life.

Announcer:
That was Dr. Omar Sinno discussing how to meet gMG patients’ needs with individualized treatment. To access this and other episodes in our series, visit Neurofrontiers on ReachMD.com, where you can Be Part of the Knowledge. Thanks for listening!